CYFIP2 serves as a prognostic biomarker and correlates with tumor immune microenvironment in human cancers
Q Peng, B Ren, K Xin, W Liu, MS Alam, Y Yang… - European Journal of …, 2023 - Springer
Background The mechanisms whereby CYFIP2 acts in tumor development and drives
immune infiltration have been poorly explored. Thus, this study aimed to identifying the role …
immune infiltration have been poorly explored. Thus, this study aimed to identifying the role …
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Z Xie, Z Zhou, S Yang, S Zhang, B Shao - Molecular Biomedicine, 2023 - Springer
The tumor microenvironment (TME) is crucial to neoplastic processes, fostering proliferation,
angiogenesis and metastasis. Epigenetic regulations, primarily including DNA and RNA …
angiogenesis and metastasis. Epigenetic regulations, primarily including DNA and RNA …
Plasma cell-free tumor methylome as a biomarker in solid tumors: biology and applications
DNA methylation is a fundamental mechanism of epigenetic control in cells and its
dysregulation is strongly implicated in cancer development. Cancers possess an extensively …
dysregulation is strongly implicated in cancer development. Cancers possess an extensively …
Epigenetic oncogenesis, biomarkers and emerging chemotherapeutics for breast cancer
Breast cancer remains one of the leading causes of cancer-related deaths globally and the
most prominent among females, yet with limited effective therapeutic options. Most of the …
most prominent among females, yet with limited effective therapeutic options. Most of the …
Druggable Metabolic Vulnerabilities are exposed and masked during progression to castration resistant prostate cancer
SYC Choi, CF Ribeiro, Y Wang, M Loda, SR Plymate… - Biomolecules, 2022 - mdpi.com
There is an urgent need for exploring new actionable targets other than androgen receptor
to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has …
to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has …
Transcriptome‐wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer
E Mariella, G Grasso, M Miotto, K Buzo… - Molecular …, 2024 - Wiley Online Library
Multiple strategies are continuously being explored to expand the drug target repertoire in
solid tumors. We devised a novel computational workflow for transcriptome‐wide gene …
solid tumors. We devised a novel computational workflow for transcriptome‐wide gene …
The role of aberrant DNA methylation in cancer initiation and clinical impacts
F Geissler, K Nesic, O Kondrashova… - Therapeutic …, 2024 - journals.sagepub.com
Epigenetic alterations, including aberrant DNA methylation, are now recognized as bone
fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy …
fide hallmarks of cancer, which can contribute to cancer initiation, progression, therapy …
Evaluation of metabolomics as diagnostic targets in oral squamous cell carcinoma: a systematic review
In recent years, high-throughput technologies have facilitated the widespread use of
metabolomics to identify biomarkers and targets for oral squamous cell carcinoma (OSCC) …
metabolomics to identify biomarkers and targets for oral squamous cell carcinoma (OSCC) …
E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of …
N Zhang, X Gao, Q Yuan, X Fu, P Wang, F Cai, H Liu… - Clinical …, 2023 - Springer
Background Downregulation of certain tumor-suppressor genes (TSGs) by aberrant
methylation of CpG islands in the promoter region contributes a great deal to the …
methylation of CpG islands in the promoter region contributes a great deal to the …
Stage-specific coexpression network analysis of Myc in cohorts of renal cancer
The present study investigates the molecular dynamics of Myc in normal precursors and in
different stages (I/II/III/IV) of cohorts of renal cancer using two distinct yet complementary …
different stages (I/II/III/IV) of cohorts of renal cancer using two distinct yet complementary …